https://www.live-feeds.com/feed/biontech-genentech-cancer-vax-records-more-deaths-than-control-in-scrapped-ph-2-testContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/biontech-genentech-cancer-vax-records-more-deaths-than-control-in-scrapped-ph-2-testhttps://www.live-feeds.com/feed/biontech-genentech-cancer-vax-records-more-deaths-than-control-in-scrapped-ph-2-test#u52642Mon, 31 Aug 2026 02:45:40 +0000BioNTech and Genentech have terminated a phase 2 trial of an mRNA vaccine for colorectal cancer following a safety review. The study recorded more deaths in the vaccine group than in the control group. This failure has affected the stock prices of other mRNA companies, including Moderna and Arcturus. The trial was stopped mid-stage, marking a significant setback for the development of mRNA-based cancer therapies.Why it mattersThe project was a collaboration between BioNTech and Genentech, a member of the Roche group. mRNA technology, which gained global prominence during the pandemic, is being